Stock Price Quote

ZIM LABORATORIES LTD.

NSE : ZIMLABBSE : 541400ISIN CODE : INE518E01015Industry : Pharmaceuticals & DrugsHouse : MNC
BSE114.001.45 (+1.29 %)
PREV CLOSE ( ) 112.55
OPEN PRICE ( ) 114.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4099
TODAY'S LOW / HIGH ( )111.00 114.85
52 WK LOW / HIGH ( )86.65 151.75
NSE113.601.1 (+0.98 %)
PREV CLOSE( ) 112.50
OPEN PRICE ( ) 114.00
BID PRICE (QTY) 113.60 (2006)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 14100
TODAY'S LOW / HIGH( ) 112.65 114.00
52 WK LOW / HIGH ( )87.9 152.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Anwar Siraj Daud - Chairman Anwar Siraj Daud - Managing Director
Registered Office

Address Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, ,
Nagpur,
Maharashtra-440013

Phone 0712-2981960

Email infa@zimlab.in

Website www.zimlab.in

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, OTCEI

NEWS

14May ZIM Laboratories gets nod to invest Rs
ZIM Laboratories has received approval for investment of upto Rs 40 lakh..
14May ZIM Laboratories gets nod to invest Rs
ZIM Laboratories has received approval for investment of upto Rs 2 crore..
26Apr Reply To The Clarification Sought On
With reference to your email dt. 25.04.2024, this is to inform you that..
25Apr Clarification sought from Zim Laborat
The Exchange has sought clarification from Zim Laboratories Ltd on April..
24Apr Reply To The Clarification Sought On
With reference to your email dt. 24.04.2024, this is to inform you that..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit78.9000000000001167.57
Gross Profit 108.03 230.41
Operating Profit 169.55447.94
Net Sales 1173.873654.73

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

NON-INSTITUTION 66.73%
PROMOTERS 33.26%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Zim Laboratories Ltd.

Zim Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 114. Its current market capitalisation stands at Rs 555.47 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3965.31 Cr and Total Income of Rs.4029.62 Cr. The company's management includes Padmakar Shrinivas Joshi, Prakash Pralhadrao Sapkal, Niraj Pukhraj Dhadiwal, Zulfiquar Murtaza Kamal, Anwar Siraj Daud, Anwar Siraj Daud, Piyush Siddeshwar Nikhade, Kakasaheb Mahadik, Kamlesh Shende, Kavita Loya.

It is listed on the BSE with a BSE Code of 541400 , NSE with an NSE Symbol of ZIMLAB and ISIN of INE518E01015. It's Registered office is at Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, Nagpur-440013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Paliwal Modani & Co, Raman S Shah & Co, SR Batliboi & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.